

30 March 2023

ASX Code: MXC

LSE Code: MXC

Results of Shareholder's General Meeting

ASX
RELEASE

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would like to announce the results from the Company's General Meeting of Shareholders held today, Thursday, 30 March 2023, in accordance with ASX Listing Rule 3.13.2.

The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried.

Details of the proxy voting and voting outcomes for all motions put to the meeting are set out in the attached report.

—Ends—

Authorised for release by the Company Secretary, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer
CEO & Managing Director
+61 8 6382 3390
info@mgcpharma.com.au

UK PR Advisors

Tavistock
Charles Vivian / Tim Pearson
+44 207 920 3150
mgcpharma@tavistock.co.uk

UK Financial and Corporate Advisor

SW4 Partners
Rupert Fane / Nilesh Patel
rupert@sw4partners.com / nilesh@sw4partners.com

MGC Pharmaceuticals Ltd

Arron Canicaïs / Rowan Harland
Joint Company Secretaries
+61 8 6382 3390
info@mgcpharma.co.uk

UK Brokers

Peterhouse Capital
Charles Goodfellow / Lucy Williams
+44 207 469 0930
cg@peterhousecap.com / lw@peterhousecap.com

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil, and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Approval to amend terms of Convertible Notes 2020	Ordinary	482,624,072 86.72%	70,706,497 12.70%	3,215,584 0.58%	51,172,777	485,839,656 87.30%	70,706,497 12.70%	51,172,777	Carried
2 Approval to amend terms of Convertible Notes 2022	Ordinary	482,406,754 86.68%	70,963,815 12.75%	3,175,584 0.57%	51,172,777	485,582,338 87.25%	70,963,815 12.75%	51,172,777	Carried
3 Ratify prior issue of Convertible Notes B 2022	Ordinary	482,701,877 86.66%	71,127,692 12.77%	3,175,584 0.57%	50,713,777	485,877,461 87.23%	71,127,692 12.77%	50,713,777	Carried
4 Approval to issue Convertible Notes (2022)	Ordinary	498,519,740 89.74%	53,693,829 9.66%	3,300,584 0.60%	52,204,777	501,820,324 90.33%	53,693,829 9.67%	52,204,777	Carried
5 Ratification of prior issue of Options	Ordinary	481,032,584 86.59%	71,334,087 12.84%	3,175,584 0.57%	52,176,675	484,208,168 87.16%	71,334,087 12.84%	52,176,675	Carried
6 Approval for Share Placement	Ordinary	549,669,914 91.04%	50,928,389 8.43%	3,151,384 0.53%	3,969,243	552,821,298 91.56%	50,928,389 8.44%	3,969,243	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.